American healthcare company
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitor ( CGM ) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacture facility in Mesa, Arizona .

history [edit ]

Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. [ 1 ] [ 2 ] In 2006, Dexcom received U.S. Food and Drug Administration ( FDA ) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day detector that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second coevals product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation [ 3 ] and Animas Corporation [ 4 ] deoxyadenosine monophosphate well as a growth agreement with Edwards Lifesciences for a continuous glucose admonisher in the intensive manage whole hospital environment. [ 5 ] During February 2009, Dexcom received blessing for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring organization, from the FDA. This product received a CE score in November 2009. In 2013, development work for consolidation with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its approaching G5 and G6 continuous glucose monitoring systems into Tandem ‘s insulin pumps. [ 6 ] The G5 was approved in 2016 by the FDA for habit as a standalone device, while the G6 gained approval in 2018. [ 7 ]

Reading: Wikipedia

Dexcom ‘s first G-series CGM, the G4 Platinum, received a CE target [ 8 ] and FDA blessing in 2012 [ 9 ] for adults ages 18 and over. This device improved hypoglycemic accuracy by 30 %. [ 9 ] It besides offered a longer roll of transmission between the detector and receiver vitamin a well as a color LCD expose. [ 9 ] The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. [ 10 ] Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the communion of CGM data with up to five other people using the “ Share ” and “ Follow ” smartphone apps. [ 11 ] The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, [ 12 ] the G5 has Bluetooth integrated into its sender, enabling it to send data to a mobile device. [ 13 ] This allows for use of the device without the standalone recipient. The Dexcom G5 received a CE cross off in September 2015. [ 14 ]

Partnerships [edit ]

Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the consolidation of its new G5 and G6 continuous glucose monitoring systems into Tandem ‘s insulin pumps. [ 15 ] [ 16 ] Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop engineering that uses Tandem ‘s deoxythymidine monophosphate : slender X2 insulin pump and the Dexcom G6 to “ to mechanically increase, decrease, or stop the rescue of insulin in reply to the glucose levels of people with Type 1 diabetes. ” [ 17 ] In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies ‘ software applications. [ 18 ]

Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to partake CGM datum from the Dexcom G6 with Livongo ’ s chopine. This integration allowed Livongo to incorporate the CGM data along with other patient data. [ 19 ] In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet ’ s tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery. [ 20 ] This allowed the ability to adjust insulin doses based on Insulet ’ s algorithm or through their smartphone. [ 21 ] The company besides announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital chopine for diabetes management. [ 22 ]

References [edit ]

beginning :
Category : Health

Leave a Reply

Your email address will not be published.